Loss And Gain: Trade War Halves China Biotech VC Funding To US, But Asian Countries May Benefit
Executive Summary
Chinese venture funding to the US biotech sector has fallen by nearly 60% in the latest sign of cooling in the previously booming bilateral life sciences investment sector.
You may also be interested in...
10 For 2020: Regulatory Trends To Watch In China
2019 was the year that China approved the first new drug for Alzheimer's in nearly two decades and for the first US approval of an original cancer drug from China. While the simmering US trade war has been addressed by a phase one agreement to be signed, other uncertainties marked a year dominated by a large vaccine scandal and resulting bankruptcy, and increasing calls to include China in global clinical development plans.
Trade War Spreads: Trump Rains On China Biotech Investment Parade
The music is ending and the party may be over; Chinese biotech investment could soon face heightened scrutiny from the Trump administration.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.